Bicalutamide

• A clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of prostate can… Pending
  2024-515194-10-00 Phase III 3 countries Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA T… Pending
  2024-520093-34-00 Phase III 1 country Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
• Sbrt±sTad for Unfavorable iNtermediate rIsk/high-risk prostate cancer (STUNNIN): A Randomized Phase II Study Recruiting
  2024-511886-12-00 Phase II 1 country I.F.O. Istituti Fisioterapici Ospitalieri
• A multicenter uncontrolled, open label, prospective non-comparative single arm phase II study with bicalutamide (an antiandrogen) in combina… Recruiting
  2022-502272-23-00 Phase II 1 country UZ Leuven
• Clinical trial of androgen deprivation therapy combined with salvage radiotherapy when treating prostate cancer that has suffered recurrence… Recruiting
  2024-517666-41-00 Phase III 1 country Instituto De Investigacion En Oncología Radioterapica FEOR
• Phase II Dutasteride in combination with CAB vs CAB in SDC (DUCT) Recruiting
  2022-500745-24-00 Phase II/III 1 country Stichting Radboud University Medical Center
• Clinical utility of a next generation sequencing-based “oncochip” for therapeutic decision in metastatic breast cancer. Study SHARP Recruiting
  2024-513934-40-00 Phase II 1 country Istituto Europeo Di Oncologia S.r.l.
• An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended
  2023-507970-42-00 Phase III 10 countries Novartis Pharma AG
• An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended
  2023-505246-26-00 Phase III 9 countries Janssen - Cilag International
• Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET Ended
  2024-516137-13-00 Phase III 1 country Cancer Trials Ireland
• Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostat… Ended
  2024-514808-13-00 Phase III 3 countries Cancer Trials Ireland

Showing 1–11 of 11 trials